|
|
|
Real Estate News Releases
|
 (EMAILWIRE.COM, February 15, 2012 ) Boston, MA -- Amyotrophic lateral sclerosis or ALS is a degenerative condition of the nerves in the brain and spinal cord. With ALS, nerve cells (neurons) waste away or die, and can no longer send messages to muscles. This eventually leads to muscle weakening, twitching, and an inability to move the arms, legs, and body. The condition slowly gets worse. When the muscles in the chest area stop working, it becomes hard or impossible to breathe on one's own. In about 10% of cases, ALS is caused by a genetic defect. In the remaining cases, the cause is unknown. ALS affects approximately 5 out of every 100,000 people worldwide. Of the wide ranging diseases known to man, some say that ALS tops the charts as the cruelest of all disease.
BrainStorm Cell Therapeutics, Inc. (OTCBB:BCLI) is breaking new scientific ground with its ongoing Phase I/II clinical study for ALS patients at the Hadassah Medical Center (Israel). Phase I is to show clinical proof of safety in patients. Dimitrios Karussis, head of Israel's Hadassah Medical Center's Multiple Sclerosis unit who is leading the clinical trial surprised the world when he announced, "Even though we are conducting a safety trial, the early clinical follow-up of the patients treated with the stem cells shows indications of beneficial clinical effects, such as an improvement in breathing and swallowing ability as well as in muscular power."
Sai Rosen, Director of Operations at Stem Cell Media, LLC commented, “While many companies are working on cellular therapies to treat ALS, BrainStorm has leveraged the proven technological approach of using patient specific bone marrow to treat disease. In doing so, BrainStorm will be able to find treatments for ALS faster and potentially reward shareholders sooner than expected.”
BrainStorm has focused its world class scientific team towards the low hanging fruit of cellular therapy by using bone marrow from a patientÂ’s own body. This is called autologous cell therapy (ACT). Bone marrow transplantation (BMT) is a relatively new medical procedure being used to treat diseases once thought incurable. Since its first successful use in 1968, BMTs have been used to treat patients diagnosed with leukemia, aplastic anemia, lymphomas such as Hodgkin's disease, multiple myeloma, immune deficiency disorders and some solid tumors such as breast and ovarian cancer. Because bone marrow transplants have a 40-year track record of proven clinical safety in humans, the translation time to market using BMTÂ’s to derive cells for treatments for ALS, MS, HuntingtonÂ’s, spinal cord maladies and other neurodegenerative disease will drastically reduce the time from the bench to the bedside.
BrainStorm has named its 21st century technology NurOwn™. The establishment of a reproducible cGMP compliant production process has Big Pharma the world over watching the BrainStorm ALS trial intently. The process begins with the removal of bone marrow from the diagnosed patient with ALS. The process separates the mesenchymal stem cells (MSC). MSC’s are incredibly powerful and can be turned into different cell types. In this use, BrainStorm switches the MSC’s into nerve-like cells capable of releasing dopamine and glial-derived neurotropic factor (GDNF). GDNF is essential for ensuring proper electrical continuity in the human body. The new secreting cells are then transplanted back into the patient. The differentiated GDNF cells are critical for maintaining axon-muscle fiber connections.
In 2011, BrainStorm was granted Orphan Drug Status for its future ALS trial. They are likely to use the clinical data from its ALS trial in Israel to bypass the need for a Phase I in the U.S. and move straight into a Phase II ALS trial. This is a win for those suffering with ALS, shareholders and for Big Pharma looking towards entering the multi-billion dollar field of neurodegenerative diseases.
Jason Gruner, Founder of Stem Cell Media, LLC, summed it as follows, “The baby-boom generation is the driving force when it comes to regenerative medicine. The total value of all U.S. household wealth in 2011 was approximately 58.2 trillion. The truth of the matter, though, is that nobody wants to get old and or say goodbye to a loved one. If you are faced with dying or buying a $240,000 heart, which one will you choose? If you can purchase new neuron cells to treat your spouse of 40 years suffering from Alzheimer’s for a measly $75,000, will you part with the condo in Boca? If Big Pharma has the ability to bring regenerative medicine to market in a scalable and efficient manner, it will usher in a paradigm shift in healthcare.”
About BrainStorm (OTC.BB:BCLI) is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient's own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury.
About Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements in the regenerative medicine sector. Investor Stem Cell is the only online forum dedicated to stem cell investors. Before investing make sure to speak with a licensed investment professional.
InvestorStemCell.com is the World's Only Online Forum Dedicated to Stem Cell Investors
Press Release Courtesy of Online PR Media: http://bit.ly/x1oGQc
Stem Cell Media, LLC.
Sai Rosen
866-754-0457
icell@investorstemcell.com 
|
|
|
|
Real Estate News by Sector
|
|
|
|
|
